Tango Therapeutics (TNGX) stock

Cancer medicines , market cap $3.5B

Cancer medicines

Worth $3.5B

$24.30

+6.86%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#103of 281

Biotech

Checks firing

4of 14

Choppy

From 52-week high

-29.3%

under its best in a year

TNGX's Quality Score rose 3 points on Tue, Nov 10, to 3. Its average daily range eased to 7.8%, under 8%.

Follow TNGX's trial news. Pro members can get an alert when Tango Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when TNGX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextJan 2027“…its Phase 1/2 clinical trial of vopimetostat monotherapy in a cohort of patients with NSCLC in January 2027…”Trial data · SEC filing · Oct 23

Why is TNGX up?

Up 6.9% today, while its biotech peers are down 1.4%; no story names it yet.

Rose on Nov 9

Up 6% on Nov 9, an up day for the market: the S&P 500 rose 2%, 84% of stocks rose, and biotech stocks a median 4%.

It reported a diluted loss of $0.39 a share that day.

Sources: Price history, Nov 9, 2026; SEC filing, Nov 9, 2026; Company release (8-K), Nov 9, 2026

1 more reason, free with an account →The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on TNGX

Key facts on TNGX
Holding it back	56.7% more shares than a year ago
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind TNGX's 3, free with an account →6 more reasons behind TNGX's 3, for Pro members.

TNGX in the news

TodayNo story names it yet.

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

TNGX catalysts

Coming up

After its last 4 reports it closed +8.7% on average, higher 2 of 4 times.

3 more coming up and 7 past catalysts since 2023, with sizes and sources, for Pro members.

What's next for TNGX, and how long its cash lasts

Next step the company has named

Jan 2027“…to report data from its Phase 1/2 clinical trial of vopimetostat monotherapy in a cohort of patients with NSCLC in January 2027 and data from its Phase 1/2 clinical trial evaluating…”Trial data · SEC filing · Oct 23

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: Vopimetostat · PDAC · Phase 1/2
Its trial: TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC PatientsPhase 1/2 · Not yet recruiting · 188 people · main data estimated Nov 2031 · NCT07897734

4 more trials, 1 more milestone and 33 filings, for Pro members.

Cash runway

The company says its cash lasts into 2030 (8-K, Jun 10).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 21, 2025)
At-the-market share sales program (424B5, filed Aug 11, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

President, R&D Adam Crystal sold 5,000 shares on Nov 2, under a planned sale. 16 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Malte Peters buys or sells

For Pro members: every trade, and Malte Peters’s 10 filings and quotes.

Get an alert when TNGX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why TNGX scores 3

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Size and Persistence.

What every line is worth, and the reason behind it, on TNGX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when TNGX's Quality Score turns up

A free account. No card.

How TNGX ranks in Biotech

TNGX is #103 of 281 by Quality Score.

How TNGX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	TGTXTG Therapeutics		Open for its score
	TLXTelix Pharmaceuticals		Open for its score
	TNXPTonix Pharmaceuticals		Open for its score
	TRDAEntrada Therapeutics		Open for its score
103	TNGXTango Therapeutics	4/14	3

Share count against a year before: TNGX +57%, BBIO +2.2%, AXSM +4.8%, ERAS +9.9%.

When does TNGX report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 114 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What TNGX reported on Nov 9, 2026

The quarter

A loss of $0.39 a share, from a profit of $0.14.

“The change was primarily due to increased spend related to the advancement of the vopimetostat and TNG456 clinical programs.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

TNGX's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase was primarily due to increased spend on personnel-related costs, including share-based compensation expense which included increases derived from the modification of previously issued equity awards for former executive officers.”

From its results filing (SEC filing · Nov 9)

2 more sentences, for Pro members.

The numbers

Market value: $3.5B; today
Sales: $0; down 100% on the year
Free cash flow: -$150M; last 12 months

Its share count grew 9.8% a year over 3 years.

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on TNGX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.5%-4.8%+5.8%

May 13Aug 11Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026Before open	Before open	+1.6%	+5.8%	not yet
Aug 11, 2026Before open	Before open	-2.2%	-4.8%	-8.6%
May 13, 2026After close	After close	-7.8%	-2.5%	-17.4%

TNGX closed higher after 2 of its last 4 reports.

All 4 reports, and TNGX's Quality Score going into each

TNGX sales and profit by year

Sales and profit by year

Sales grew in four of the last five years, to $62.4M in 2025. It lost money in each of the six years.

TNGX has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on TNGX, and all 14 on every stock.Get in free →

TNGX RSI today: 54.1, above its 50-day and 200-day averages

Not scored

RSI 54.1, MACD above signal, above both averages. Not scored.13 readings

The deep dive on TNGX

What it does and how it makes money4 findingsAn operating loss of $111M in fiscal 2025, on $62.4M of sales.Annual report, filed Mar 5, 2026"Additionally, we exclusively own five patent families covering other PRMT5 inhibitors and their methods of use with expiration dates ranging from 2039 to 2043." (10-K for fiscal 2025)SEC filing · Mar 5, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades TNGX, for Pro members
Against its closest peers4 peersShare count against a year before: TNGX +57%, BBIO +2.2%, AXSM +4.8%, ERAS +9.9%.

3 more findings on TNGX, each with its source, for Pro members.

TNGX share count over time

Shares: 56.7% more than a year ago (to Sep 30).

Shares of TNGX outstanding, as filed
Shares outstanding	As of
169.5M	Nov 2, 2026
168.6M	Aug 4, 2026
144.6M	May 6, 2026
142.7M	Feb 26, 2026

Offerings, shelves, and splits of TNGX, from its filings
From its filings	Filed
Set up an at-the-market program for up to $400M of shares, about 11% of its market value	Aug 11, 2026
Priced a sale of shares	Jun 10, 2026
Registered shares for a later sale (S-3ASR)	Nov 21, 2025
Registered shares for a later sale (S-3)	Nov 21, 2025

TNGX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Malte PetersPresident & CEO · no trades on file
Barbara WeberDirector, Executive Chair · 2 trades
Daniella BeckmanChief Financial Officer · 2 trades
Matthew GallChief Financial Officer · no trades on file
Adam CrystalPresident, R&D · 14 trades
Jessica NewcombPrincipal Accounting Officer · 2 trades
Sung LeeDirector · no trades on file
John B. KetchumDirector · no trades on file

3 more officers and directors file at TNGX.

See insider trades by person

Which ETFs hold TNGX?

In ETFs: TNGX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

137 employeesBoston, MAtangotx.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on TNGX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn TNGX's score around: 8 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

See TNGX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: TNGX's Quality Score is 3 (Below Average), #103 of 281 in Biotech.

What does TNGX's Quality Score say?

TNGX scores 3 today, which Breakaway calls Below Average. It is #103 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 6% on Nov 9, an up day for the market: the S&P 500 rose 2%, 84% of stocks rose, and biotech stocks a median 4%. Shares: 56.7% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is TNGX's Quality Score?

TNGX scores 3 today, which Breakaway calls Below Average (0 to 5). That is #103 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TNGX's 3.

When does TNGX report earnings?

Expected to report Thu Mar 4, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. TNGX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.